Aytu BioScience, Inc. (AYTU): Price and Financial Metrics


Aytu BioScience, Inc. (AYTU): $3.31

-0.03 (-0.90%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AYTU to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AYTU Stock Summary

  • AYTU's price/sales ratio is 0.1; that's higher than the P/S ratio of just 1.86% of US stocks.
  • In terms of volatility of its share price, AYTU is more volatile than 99.56% of stocks we're observing.
  • AYTU BIOPHARMA INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -197.25%, greater than the shareholder yield of merely 2.97% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to AYTU BIOPHARMA INC, a group of peers worth examining would be PTPI, XRX, EHTH, FLNT, and HAS.
  • Visit AYTU's SEC page to see the company's official filings. To visit the company's web site, go to aytubio.com.

AYTU Valuation Summary

  • AYTU's EV/EBIT ratio is -0.1; this is 101.01% lower than that of the median Healthcare stock.
  • Over the past 95 months, AYTU's price/earnings ratio has gone down 0.1.

Below are key valuation metrics over time for AYTU.

Stock Date P/S P/B P/E EV/EBIT
AYTU 2023-01-20 0.1 0.2 -0.1 -0.1
AYTU 2023-01-19 0.1 0.2 -0.1 -0.1
AYTU 2023-01-18 0.1 0.2 -0.1 -0.1
AYTU 2023-01-17 0.1 0.2 -0.1 -0.1
AYTU 2023-01-13 0.1 0.2 -0.1 -0.1
AYTU 2023-01-12 0.1 0.2 -0.1 -0.1

AYTU's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AYTU has a Quality Grade of D, ranking ahead of 15.62% of graded US stocks.
  • AYTU's asset turnover comes in at 0.311 -- ranking 147th of 682 Pharmaceutical Products stocks.
  • SYRS, ONVO, and GTHX are the stocks whose asset turnover ratios are most correlated with AYTU.

The table below shows AYTU's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.311 0.445 -6.155
2021-03-31 0.311 0.508 -2.810
2020-12-31 0.334 0.683 -2.327
2020-09-30 0.301 0.723 -2.482
2020-06-30 0.265 0.727 -23.603
2020-03-31 0.194 0.749 8.971

AYTU Price Target

For more insight on analysts targets of AYTU, see our AYTU price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $17.50 Average Broker Recommendation 1.5 (Moderate Buy)

AYTU Stock Price Chart Interactive Chart >

Price chart for AYTU

AYTU Price/Volume Stats

Current price $3.31 52-week high $29.00
Prev. close $3.34 52-week low $2.96
Day low $3.28 Volume 37,600
Day high $3.36 Avg. volume 130,560
50-day MA $3.93 Dividend yield N/A
200-day MA $7.19 Market Cap 10.33M

Aytu BioScience, Inc. (AYTU) Company Bio


Aytu BioScience, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. Aytu BioScience, Inc. is based in Englewood, Colorado.


AYTU Latest News Stream


Event/Time News Detail
Loading, please wait...

AYTU Latest Social Stream


Loading social stream, please wait...

View Full AYTU Social Stream

Latest AYTU News From Around the Web

Below are the latest news stories about AYTU BIOPHARMA INC that investors may wish to consider to help them evaluate AYTU as an investment opportunity.

Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance

/ Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") notifying the Company that it has regained compliance with the Nasdaq's minimum bid price requirement.

Yahoo | January 25, 2023

Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31

/ Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced that Josh Disbrow, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023.

Yahoo | January 24, 2023

Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients

Millions of ADHD patients in the United States rely on FDA approved treatments to control their ADHD symptoms and many of them are currently struggling to fill their prescription due to a prolonged supply disruption for generic Adderall XR (mixed salts of a single-entity amphetamine product) extended-release capsules, CII. Many of these patients may not be aware that there's an FDA-approved, bioequivalent treatment option which is widely available.

Yahoo | January 10, 2023

Aytu BioPharma Announces 1-for-20 Reverse Stock Split

Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced a 1-for-20 reverse stock split of its outstanding common stock, effective at 12:01 a.m. Eastern time on January 6, 2023. Beginning tomorrow, January 6, 2023, the Company's common stock will trade on a split-adjusted basis.

Yahoo | January 5, 2023

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2023 Earnings Call Transcript

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2023 Earnings Call Transcript November 14, 2022 Aytu BioPharma, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.18. Operator: Good afternoon, ladies and gentlemen, and welcome to the Aytu BioPharma Fiscal 2023 Q1 Results Call. At this time, all participants are placed on a listen-only mode and the […]

Yahoo | December 29, 2022

Read More 'AYTU' Stories Here

AYTU Price Returns

1-mo -10.64%
3-mo -1.14%
6-mo -67.49%
1-year -85.61%
3-year -97.91%
5-year -99.97%
YTD -12.43%
2022 -86.00%
2021 -77.42%
2020 -38.51%
2019 23.10%
2018 -98.23%

Continue Researching AYTU

Here are a few links from around the web to help you further your research on Aytu Bioscience Inc's stock as an investment opportunity:

Aytu Bioscience Inc (AYTU) Stock Price | Nasdaq
Aytu Bioscience Inc (AYTU) Stock Quote, History and News - Yahoo Finance
Aytu Bioscience Inc (AYTU) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 12.9407 seconds.